ÂÜÀòÂÒÂ×

Mr. Brancaccio is currently the chief financial officer of an incubator for venture backed medical device companies. He also serves on the boards of Alfacell Corporation and Xenomics, Inc. which are publicly traded biopharmaceutical companies where he is either the chairman or a member of their Audit Committees, Compensation Committees or Nominating Committees. He was formerly the secretary and treasurer of Memory Pharmaceuticals Corporation after serving in the capacity of their acting chief financial officer. Prior to Memory Pharmaceuticals, Mr. Brancaccio held the positions of chief financial officer and chief operating officer of Eline Group, a publicly traded entertainment and media company, where he oversaw the roll up of several related companies into the group and completed private equity financing placements. Prior to joining Eline Group, he held a number of senior executive positions in public and private companies including Atlantic Pharmaceuticals, Zambon Corporation, Deven International and Health Learning Systems. During his tenure with these companies he participated in initial public offerings and the negotiating of licensing and development agreements within both the pharmaceutical and biotechnology industries. He is a retired Certified Public Accountant and has a degree in Accounting from Seton Hall University.